Using a large nationwide electronic database, researchers assessed the association between giant cell arteritis and risk for malignancies.
The American College of Rheumatology and Vasculitis Foundation released evidence-based recommendations for the management of giant cell arteritis and Takayasu arteritis.
Researchers assessed the sensitivity of ultrasound halo features and their association with disease activity and glucocorticoid treatment in patients with newly diagnosed giant cell arteritis.
Researchers compared the efficacy and adverse events of reduced-dose and high-dose glucocorticoid plus rituximab regimens for remission induction of ANCA-associated vasculitis.
Researchers determined the prevalence VEXAS in patients with relapsing polychondritis, assessed clinical, laboratory, and immunologic features, and developed a clinical algorithm to inform genetic screening for VEXAS in this population.
Researchers studied the association between steroid therapy and glucocorticoid toxicity in patients with ANCA-associated vasculitis.
Researchers described diagnostic delays and the factors associated with time to diagnosis in patients with vasculitis.
Authors presented the case of a 48-year-old woman with rheumatoid arthritis, newly diagnosed microscopic polyangiitis, and a recent COVID-19 infection who stopped taking immunosuppressive therapy.
Researchers aimed to estimate the mortality rates of primary systemic vasculitis and its geographic distribution, using recent population data in the US.
Researchers assessed the role of trimethoprim/sulfametoxazole in reducing relapse rate in patients with granulomatosis with polyangiitis and infection risk in patients with ANCA-associated vasculitis.